American Heart Journal
Volume 152, Issue 4 , Pages 684.e1-684.e9 , October 2006

Age, outcomes, and treatment effects of fibrinolytic and antithrombotic combinations: Findings from Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT)-3 and ASSENT-3 PLUS

  • Peter R. Sinnaeve, MD, PhD

      Affiliations

    • Department of Cardiology, University Hospital Gasthuisberg, Leuven, Belgium
    • Corresponding Author InformationReprint requests: Peter R. Sinnaeve, MD, PhD, Department of Cardiology, University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium.
    • ,
  • Yao Huang, PhD

      Affiliations

    • Duke Clinical Research Center, Durham, NC
    • ,
  • Kris Bogaerts, PhD

      Affiliations

    • Department of Cardiology, University Hospital Gasthuisberg, Leuven, Belgium
    • ,
  • Alec Vahanian, MD, PhD

      Affiliations

    • Cardiology Department, Bichat Hospital, Paris, France
    • ,
  • Jennifer Adgey, MD, PhD

      Affiliations

    • Regional Medical Cardiology Centre, Royal Victoria Hospital, Belfast, Northern Ireland
    • ,
  • Paul W. Armstrong, MD

      Affiliations

    • Department of Cardiology, University of Alberta, Edmonton, Canada
    • ,
  • Lars Wallentin, MD

      Affiliations

    • Department of Cardiology University Hospital, Uppsala, Sweden
    • ,
  • Frans J. Van de Werf, MD, PhD

      Affiliations

    • Department of Cardiology, University Hospital Gasthuisberg, Leuven, Belgium
    • ,
  • Christopher B. Granger, MD

      Affiliations

    • Duke Clinical Research Center, Durham, NC
    • ,
  • on behalf of the ASSENT-3 and ASSENT-3 PLUS investigators

Received 5 October 2005 ,Accepted 3 July 2006.

References 

  1. Lee KL, Woodlief LH, Topol EJ, et al. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. Results from an international trial of 41,021 patients. GUSTO-I Investigators. Circulation. 1995;91:1659
  2. Stevenson R, Ranjadayalan K, Wilkinson P, et al. Short and long term prognosis of acute myocardial infarction since introduction of thrombolysis. BMJ. 1993;307:349
  3. Goldberg RJ, McCormick D, Gurwitz JH, et al. Age-related trends in short-and long-term survival after acute myocardial infarction: a 20-year population-based perspective (1975-1995). Am J Cardiol. 1998;82:1311
  4. Maggioni AP, Maseri A, Fresco C, et al. Age-related increase in mortality among patients with first myocardial infarctions treated with thrombolysis. The investigators of the gruppo italiano per lo studio della sopravvivenza nell'infarto miocardico (GISSI-2). N Engl J Med. 1993;329:1442
  5. Paul SD, O'Gara PT, Mahjoub ZA, et al. Geriatric patients with acute myocardial infarction: cardiac risk factor profiles, presentation, thrombolysis, coronary interventions, and prognosis. Am Heart J. 1996;131:710
  6. Thiemann DR, Coresh J, Schulman SP, et al. Lack of benefit for intravenous thrombolysis in patients with myocardial infarction who are older than 75 years. Circulation. 2000;101:2239
  7. Weaver WD, Litwin PE, Martin JS, et al. Effect of age on use of thrombolytic therapy and mortality in acute myocardial infarction. The MITI Project Group. J Am Coll Cardiol. 1991;18:657
  8. White HD, Barbash GI, Califf RM, et al. Age and outcome with contemporary thrombolytic therapy. Results from the GUSTO-I trial. Global utilization of streptokinase and TPA for occluded coronary arteries trial. Circulation. 1996;94:1826
  9. Antman EM, Gibson CM, de Lemos JA, et al. Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14. The thrombolysis in myocardial infarction (TIMI) 14 Investigators. Eur Heart J. 2000;21:1944
  10. Giugliano RP, Roe M, Harrington R, et al. Combination reperfusion therapy with eptifibatide and reduced dose tenecteplase for ST-elevation myocardial infarction: results of the Integrilin and tenecteplase in acute myocardial infarction trial (INTEGRITI) phase II angiographic trial. J Am Coll Cardiol. 2003;14:1251–1260
  11. Topol EJ. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet. 2001;357:1905
  12. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet. 2001;358:605
  13. Wallentin L, Goldstein P, Armstrong PW, et al. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the assessment of the safety and efficacy of a new thrombolytic regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. Circulation. 2003;108:135
  14. Montalescot G, Barragan P, Wittenberg O, et al. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction. N Engl J Med. 2001;344:1895
  15. Casterella PJ, Kereiakes DJ, Steinhubl SR, et al. The platelet function dose-response to abciximab during percutaneous coronary revascularization is variable. Catheter Cardiovasc Interv. 2001;54:497
  16. Becker RC, Spencer FA, Gibson M, et al. Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non–ST-segment elevation acute coronary syndromes. Am Heart J. 2002;143:753
  17. Sabatine MS, Morrow DA, Montalescot G, et al. Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 Trial. Circulation. 2005;112:3846–3854
  18. Antman EM, Morrow DA, McCabe CH, et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med. 2006;354:1477–1488
  19. Montalescot G, Collet JP, Tanguy ML, et al. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin. Circulation. 2004;110:392–398
  20. Baird SH, Menown IB, McBride SJ, et al. Randomized comparison of enoxaparin with unfractionated heparin following fibrinolytic therapy for acute myocardial infarction. Eur Heart J. 2002;23:627
  21. Tran CT, Laupacis A, Mamdani MM, et al. Effect of age on the use of evidence-based therapies for acute myocardial infarction. Am Heart J. 2004;148:834–841
  22. Spencer FA, Goldberg RJ, Frederick PD, et al. Age and the utilization of cardiac catheterization following uncomplicated first acute myocardial infarction treated with thrombolytic therapy (The Second National Registry of Myocardial Infarction [NRMI-2]). Am J Cardiol. 2001;88:107
  23. Alexander KP, Galanos AN, Jollis JG, et al. Post-myocardial infarction risk stratification in elderly patients. Am Heart J. 2001;142:37
  24. Aguirre FV, McMahon RP, Mueller H, et al. Impact of age on clinical outcome and postlytic management strategies in patients treated with intravenous thrombolytic therapy. Results from the TIMI II Study. TIMI II Investigators. Circulation. 1994;90:78

PII: S0002-8703(06)00631-4

doi: 10.1016/j.ahj.2006.07.005

American Heart Journal
Volume 152, Issue 4 , Pages 684.e1-684.e9 , October 2006

Article Tools

* Image Usage & Resolution